GA-STONEBRANCH
27.2.2024 19:25:26 CET | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry.
New Customer and Partner Relationships Fuel Growth
In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach.
Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations continue to navigate the complexities of digital transformation, Stonebranch continues to be a provider and partner of choice. It's inspiring to see such a wide array of organizations recognize the value of our solutions, and we’re excited to shape the future of IT automation with them.”
Universal Automation Center Elevates User Experience
Stonebranch introduced substantial enhancements to the Universal Automation Center (UAC) platform in 2023, focusing on elevating the user experience and broadening the scope of automation capabilities for IT Ops, DataOps, MLOps, and CloudOps professionals. Key highlights include the launch of:
- Observability with OpenTelemetry: UAC 7.5 introduced the OpenTelemetry connector, which makes telemetry data available via the OpenTelemetry standards. This feature collects log, metric, and trace data from UAC and third-party applications integrated with the UAC. Then, it outputs that collected data to application performance management (APM) tools (like Splunk, Dynatrace, and DataDog) and observability/business intelligence tools (like Grafana, Jaeger, and PowerBI).
- SAP Enhanced View: UAC has always made it easy for IT Ops teams to manage SAP tasks. With the release of UAC 7.5, Stonebranch extended this ease to business users too, by rolling out a new guided interface that’s intuitive for anyone who usually works with SAP ECC or S/4HANA.
- Jobs-as-Code: Building on UAC’s DevOps capabilities, jobs-as-code enables developers to manage jobs and workflow configuration just like business application code — directly from their integrated development environment (IDE) of choice. Additionally, by integrating UAC with source control repositories like GitHub, GitLab, and Azure DevOps, developers can establish continuous delivery pipelines that offer version control, testing capabilities, and CI/CD best practices.
- Strategic Integrations for a Connected Ecosystem: 2023 also marked the debut of several pivotal integrations, reinforcing Stonebranch's commitment to foster a more connected and agile IT ecosystem. New integrations include SAP IBP and SAP HANA XSA, DBT, Azure Synapse, SQL OBDC, Fivetran, Databricks, Temenos, Oracle EBS, Azure AZ CLI, Google Cloud Composer, and Red Hat OpenShift. These additions enhance UAC’s ability to seamlessly connect and orchestrate across diverse IT landscapes, driving unparalleled efficiency and innovation.
"Innovation is at the heart of everything we do at Stonebranch,” says Stonebranch CTO Peter Baljet. “Our commitment as a product leader is driven by our customers' rapidly evolving needs as they adopt new IT landscape paradigms. Looking ahead, we aim to enable businesses with the full potential of automation, transforming their operations and setting new levels for agility, observability, and scalability."
Accolades Celebrate Excellence at Stonebranch
Stonebranch is consistently recognized for its innovation, leadership, and workplace culture by prestigious organizations and industry analysts. These accolades highlight Stonebranch's commitment to providing cutting-edge automation solutions and fostering a supportive, dynamic work environment. Some of the notable recognition Stonebranch received in 2023 include:
- Gartner®: The research and consulting firm recognized Stonebranch in a variety of reports and guides in 2023, such as the Market Guide for Service Orchestration and Automation Platforms (SOAPs), Data and Analytics Essentials: DataOps Report, Hype Cycle for IT Infrastructure and Operations (I&O), and more.
- EMA: As a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration, Stonebranch was recognized as a “top-tier orchestrator capable of automation on-premises and in the cloud.”
- G2: In its reports for workload automation and managed file transfer, the peer-review platform awarded Stonebranch three Leader badges, a High-Performer badge, and an Easiest Doing Business With badge.
- Atlanta Journal-Constitution / Energage: Based solely on employee feedback, Stonebranch was recognized as a Metro Atlanta Top Workplace for the second consecutive year.
“These awards and recognitions are not just milestones but also motivation for us at Stonebranch,” noted Damiani. “As we celebrate these achievements, we remain focused on pushing the boundaries of what's possible in IT automation and orchestration.”
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227593444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom